Advertisement
YOU ARE HERE: LAT HomeCollectionsVectibix Drug
IN THE NEWS

Vectibix Drug

FEATURED ARTICLES
BUSINESS
March 23, 2007 | From Reuters
Amgen Inc. said Thursday that it discontinued a key clinical trial of colon cancer treatment Vectibix after discovering that the drug reduced chances of survival. Amgen said an interim look at the trial found that colon cancer patients treated only with chemotherapy and Avastin, a biologic cancer drug sold by Genentech Inc., were more likely to live than patients who also received Vectibix.
ARTICLES BY DATE
BUSINESS
May 26, 2007 | Daniel Costello, Times Staff Writer
Amgen Inc.'s annus horribilis continues. On Friday, the Thousand Oaks-based biotech giant received a series of bad news that follows negative developments in recent months. First, experts from the European Union's drug regulator recommended that the company's high-profile cancer drug Vectibix not be approved, dealing the company another financial and psychological blow.
Advertisement
BUSINESS
May 26, 2007 | Daniel Costello, Times Staff Writer
Amgen Inc.'s annus horribilis continues. On Friday, the Thousand Oaks-based biotech giant received a series of bad news that follows negative developments in recent months. First, experts from the European Union's drug regulator recommended that the company's high-profile cancer drug Vectibix not be approved, dealing the company another financial and psychological blow.
BUSINESS
March 23, 2007 | From Reuters
Amgen Inc. said Thursday that it discontinued a key clinical trial of colon cancer treatment Vectibix after discovering that the drug reduced chances of survival. Amgen said an interim look at the trial found that colon cancer patients treated only with chemotherapy and Avastin, a biologic cancer drug sold by Genentech Inc., were more likely to live than patients who also received Vectibix.
Los Angeles Times Articles
|